Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

NCT02071862 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT02071862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02071862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
March 31, 2019
Enrollment
210 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

fumarate hydratase (fh)-deficient tumors, mesothelioma, non small cell lung cancer, renal cell carcinoma, solid tumors, succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist), succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors, triple-negative breast cancer, tumors harboring amplifications in the cmyc gene, tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations